Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study

PURPOSE: Among postmenopausal women with endocrine-responsive breast cancer, the aromatase inhibitor letrozole, when compared with tamoxifen, has been shown to significantly improve disease-free survival (DFS) and time to distant recurrence (TDR). We investigated whether letrozole monotherapy prolon...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Colleoni, Marco, Giobbie-Hurder, Anita, Regan, Meredith M., Thürlimann, Beat, Mouridsen, Henning, Mauriac, Louis, Forbes, John F., Paridaens, Robert, Láng, István, Smith, Ian, Chirgwin, Jacquie, Pienkowski, Tadeusz, Wardley, Andrew, Price, Karen N., Gelber, Richard D., Coates, Alan S., Goldhirsch, Aron
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2011
Sujets:
Original Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3083867/
https://ncbi.nlm.nih.gov/pubmed/21321298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.6455
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires